Latest Diagnostic Imaging News

Page 1 of 3
TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.
Ada Torres
Ada Torres
22 Dec 2025
Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.
Ada Torres
Ada Torres
22 Dec 2025
Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.
Ada Torres
Ada Torres
22 Dec 2025
Enlitic has been authorised as one of two approved vendors by Philips to deliver AI-powered DICOM data migration solutions, marking a significant expansion in their partnership and positioning Enlitic for growth in the global radiology market.
Ada Torres
Ada Torres
25 Nov 2025
Pro Medicus Limited’s U.S. arm has secured a significant five-year, A$44 million contract to deploy its cloud-based Visage 7 imaging platform with Advanced Radiology Management, marking a strategic expansion in North America.
Ada Torres
Ada Torres
17 Nov 2025
Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.
Ada Torres
Ada Torres
10 Nov 2025
Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.
Ada Torres
Ada Torres
31 Oct 2025
Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.
Ada Torres
Ada Torres
14 Oct 2025
Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.
Victor Sage
Victor Sage
7 Oct 2025
Micro-X has landed a $3.3 million order from the Malaysian Ministry of Health for its Rover Plus mobile X-ray units, marking a significant step in its Southeast Asian expansion. Delivery is set to begin in October 2025.
Victor Sage
Victor Sage
3 Oct 2025
Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.
Ada Torres
Ada Torres
9 Sept 2025
Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.
Ada Torres
Ada Torres
8 Sept 2025